275 related articles for article (PubMed ID: 36006707)
21. Epigenetic inactivation of ERF reactivates γ-globin expression in β-thalassemia.
Bao X; Zhang X; Wang L; Wang Z; Huang J; Zhang Q; Ye Y; Liu Y; Chen D; Zuo Y; Liu Q; Xu P; Huang B; Fang J; Lao J; Feng X; Li Y; Kurita R; Nakamura Y; Yu W; Ju C; Huang C; Mohandas N; Li D; Zhao C; Xu X
Am J Hum Genet; 2021 Apr; 108(4):709-721. PubMed ID: 33735615
[TBL] [Abstract][Full Text] [Related]
22. In vivo HSC prime editing rescues sickle cell disease in a mouse model.
Li C; Georgakopoulou A; Newby GA; Chen PJ; Everette KA; Paschoudi K; Vlachaki E; Gil S; Anderson AK; Koob T; Huang L; Wang H; Kiem HP; Liu DR; Yannaki E; Lieber A
Blood; 2023 Apr; 141(17):2085-2099. PubMed ID: 36800642
[TBL] [Abstract][Full Text] [Related]
23. Therapeutic base editing of human hematopoietic stem cells.
Zeng J; Wu Y; Ren C; Bonanno J; Shen AH; Shea D; Gehrke JM; Clement K; Luk K; Yao Q; Kim R; Wolfe SA; Manis JP; Pinello L; Joung JK; Bauer DE
Nat Med; 2020 Apr; 26(4):535-541. PubMed ID: 32284612
[TBL] [Abstract][Full Text] [Related]
24. Featured Article: Modulation of fetal hemoglobin in hereditary persistence of fetal hemoglobin deletion type-2, compared to Sicilian δβ-thalassemia, by BCL11A and SOX6-targeting microRNAs.
Fornari TA; Lanaro C; Albuquerque DM; Ferreira R; Costa FF
Exp Biol Med (Maywood); 2017 Feb; 242(3):267-274. PubMed ID: 27591578
[TBL] [Abstract][Full Text] [Related]
25. Induction of fetal hemoglobin synthesis by CRISPR/Cas9-mediated editing of the human β-globin locus.
Antoniani C; Meneghini V; Lattanzi A; Felix T; Romano O; Magrin E; Weber L; Pavani G; El Hoss S; Kurita R; Nakamura Y; Cradick TJ; Lundberg AS; Porteus M; Amendola M; El Nemer W; Cavazzana M; Mavilio F; Miccio A
Blood; 2018 Apr; 131(17):1960-1973. PubMed ID: 29519807
[TBL] [Abstract][Full Text] [Related]
26. Reactivation of γ-globin expression using a minicircle DNA system to treat β-thalassemia.
Ma SP; Gao XX; Zhou GQ; Zhang HK; Yang JM; Wang WJ; Song XM; Chen HY; Lu DR
Gene; 2022 Apr; 820():146289. PubMed ID: 35143940
[TBL] [Abstract][Full Text] [Related]
27. Wake-up Sleepy Gene: Reactivating Fetal Globin for β-Hemoglobinopathies.
Wienert B; Martyn GE; Funnell APW; Quinlan KGR; Crossley M
Trends Genet; 2018 Dec; 34(12):927-940. PubMed ID: 30287096
[TBL] [Abstract][Full Text] [Related]
28. Natural regulatory mutations elevate the fetal globin gene via disruption of BCL11A or ZBTB7A binding.
Martyn GE; Wienert B; Yang L; Shah M; Norton LJ; Burdach J; Kurita R; Nakamura Y; Pearson RCM; Funnell APW; Quinlan KGR; Crossley M
Nat Genet; 2018 Apr; 50(4):498-503. PubMed ID: 29610478
[TBL] [Abstract][Full Text] [Related]
29. Original Research: Generation of non-deletional hereditary persistence of fetal hemoglobin β-globin locus yeast artificial chromosome transgenic mouse models: -175 Black HPFH and -195 Brazilian HPFH.
Braghini CA; Costa FC; Fedosyuk H; Neades RY; Novikova LV; Parker MP; Winefield RD; Peterson KR
Exp Biol Med (Maywood); 2016 Apr; 241(7):697-705. PubMed ID: 26946532
[TBL] [Abstract][Full Text] [Related]
30. Cilostazol-mediated reversion of γ-globin silencing is associated with a high level of HbF production: A potential therapeutic candidate for β-globin disorders.
Ali H; Khan F; Musharraf SG
Biomed Pharmacother; 2021 Oct; 142():112058. PubMed ID: 34426256
[TBL] [Abstract][Full Text] [Related]
31. Hematopoietic Stem Cell Gene-Addition/Editing Therapy in Sickle Cell Disease.
Germino-Watnick P; Hinds M; Le A; Chu R; Liu X; Uchida N
Cells; 2022 Jun; 11(11):. PubMed ID: 35681538
[TBL] [Abstract][Full Text] [Related]
32. CRISPR/Cas9-based multiplex genome editing of BCL11A and HBG efficiently induces fetal hemoglobin expression.
Han Y; Tan X; Jin T; Zhao S; Hu L; Zhang W; Kurita R; Nakamura Y; Liu J; Li D; Zhang Z; Fang X; Huang S
Eur J Pharmacol; 2022 Mar; 918():174788. PubMed ID: 35093321
[TBL] [Abstract][Full Text] [Related]
33. Genome Editing for the β-Hemoglobinopathies.
Porteus MH
Adv Exp Med Biol; 2017; 1013():203-217. PubMed ID: 29127682
[TBL] [Abstract][Full Text] [Related]
34. Enhanced HbF reactivation by multiplex mutagenesis of thalassemic CD34+ cells in vitro and in vivo.
Psatha N; Georgakopoulou A; Li C; Nandakumar V; Georgolopoulos G; Acosta R; Paschoudi K; Nelson J; Chee D; Athanasiadou A; Kouvatsi A; Funnell APW; Lieber A; Yannaki E; Papayannopoulou T
Blood; 2021 Oct; 138(17):1540-1553. PubMed ID: 34086867
[TBL] [Abstract][Full Text] [Related]
35. Base editing of haematopoietic stem cells rescues sickle cell disease in mice.
Newby GA; Yen JS; Woodard KJ; Mayuranathan T; Lazzarotto CR; Li Y; Sheppard-Tillman H; Porter SN; Yao Y; Mayberry K; Everette KA; Jang Y; Podracky CJ; Thaman E; Lechauve C; Sharma A; Henderson JM; Richter MF; Zhao KT; Miller SM; Wang T; Koblan LW; McCaffrey AP; Tisdale JF; Kalfa TA; Pruett-Miller SM; Tsai SQ; Weiss MJ; Liu DR
Nature; 2021 Jul; 595(7866):295-302. PubMed ID: 34079130
[TBL] [Abstract][Full Text] [Related]
36. CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia.
Frangoul H; Altshuler D; Cappellini MD; Chen YS; Domm J; Eustace BK; Foell J; de la Fuente J; Grupp S; Handgretinger R; Ho TW; Kattamis A; Kernytsky A; Lekstrom-Himes J; Li AM; Locatelli F; Mapara MY; de Montalembert M; Rondelli D; Sharma A; Sheth S; Soni S; Steinberg MH; Wall D; Yen A; Corbacioglu S
N Engl J Med; 2021 Jan; 384(3):252-260. PubMed ID: 33283989
[TBL] [Abstract][Full Text] [Related]
37. Comparative targeting analysis of KLF1, BCL11A, and HBG1/2 in CD34
Lamsfus-Calle A; Daniel-Moreno A; Antony JS; Epting T; Heumos L; Baskaran P; Admard J; Casadei N; Latifi N; Siegmund DM; Kormann MSD; Handgretinger R; Mezger M
Sci Rep; 2020 Jun; 10(1):10133. PubMed ID: 32576837
[TBL] [Abstract][Full Text] [Related]
38. The Novel Role of the B-Cell Lymphoma/Leukemia 11A (BCL11A) Gene in β-Thalassaemia Treatment.
Mahmoud Ahmed NH; Lai MI
Cardiovasc Hematol Disord Drug Targets; 2023; 22(4):226-236. PubMed ID: 36734897
[TBL] [Abstract][Full Text] [Related]
39. Editing outside the body: Ex vivo gene-modification for β-hemoglobinopathy cellular therapy.
Rosanwo TO; Bauer DE
Mol Ther; 2021 Nov; 29(11):3163-3178. PubMed ID: 34628053
[TBL] [Abstract][Full Text] [Related]
40. In Vivo HSC Gene Therapy Using a Bi-modular HDAd5/35++ Vector Cures Sickle Cell Disease in a Mouse Model.
Li C; Wang H; Georgakopoulou A; Gil S; Yannaki E; Lieber A
Mol Ther; 2021 Feb; 29(2):822-837. PubMed ID: 32949495
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
